Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arijit Ganguli

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Clinical Therapeutics|July 19, 2017
Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center SettingJordana Schmier, Kristine Ogden, Nancy Nickman, et al.
Arthritis Care & Research|November 12, 2015
Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient RegistryVibeke Strand, Jeffrey D Greenberg, Jenny Griffith, et al.
Future Oncology (London, England)|July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPCAndrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Patient Preference and Adherence|October 2, 2019
Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial populationDiana Brixner, Manish Mittal, David T Rubin, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
BMC Rheumatology|March 20, 2019
Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritisVibeke Strand, M Elaine Husni, Keith A Betts, et al.
Rheumatology (Oxford, England)|March 25, 2017
Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registryArthur Kavanaugh, Edward Keystone, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Frontiers in Oncology|September 15, 2025
Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysisArmen Aprikian, Andrew Chilelli, Thomas McLean, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Clinical Therapeutics|July 19, 2017
Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center SettingJordana Schmier, Kristine Ogden, Nancy Nickman, et al.
Arthritis Care & Research|November 12, 2015
Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient RegistryVibeke Strand, Jeffrey D Greenberg, Jenny Griffith, et al.
Future Oncology (London, England)|July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPCAndrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Patient Preference and Adherence|October 2, 2019
Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial populationDiana Brixner, Manish Mittal, David T Rubin, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
BMC Rheumatology|March 20, 2019
Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritisVibeke Strand, M Elaine Husni, Keith A Betts, et al.
Rheumatology (Oxford, England)|March 25, 2017
Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registryArthur Kavanaugh, Edward Keystone, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Frontiers in Oncology|September 15, 2025
Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysisArmen Aprikian, Andrew Chilelli, Thomas McLean, et al.
Pageof 7